Search results for "diuretics"

showing 10 items of 85 documents

Intravenous high-dose furosemide and hypertonic saline solutions for refractory heart failure and ascites.

2011

Several studies have shown the efficacy of hypertonic saline solution infusion in conditions in which regional organ blood flow is impaired. Our group has shown that treatment of patients with diuretic-resistant heart failure with high-dose furosemide plus hypertonic saline is effective and well tolerated, improving symptoms of congestion, reducing plasma levels of markers of neurohormonal and inflammatory activation, decreasing hospital readmission rates, and reducing long-term mortality. The same regimen was shown to be better than repeated paracentesis in patients with cirrhosis and refractory ascites, yielding better control of ascites, pleural effusions, and/or leg edema without an inc…

Liver CirrhosisCirrhosisFurosemideAscitesmedicineParacentesisHumansAdverse effectDiureticsInfusions IntravenousHepatic encephalopathyHeart FailureSaline Solution Hypertonicmedicine.diagnostic_testCardio-Renal Syndromebusiness.industryFurosemideAscitesmedicine.diseaseHypertonic salineNephrologyAnesthesiaHeart failuremedicine.symptombusinessmedicine.drugSeminars in nephrology
researchProduct

Immune-inflammatory and metabolic effects of high dose furosemide plus hypertonic saline solution (HSS) treatment in cirrhotic subjects with refracto…

2016

Introduction Patients with chronic liver diseases are usually thin as a result of hypermetabolism and malnutrition expressed by reduced levels of leptin and impairment of other adyponectins such as visfatin. Aims We evaluated the metabolic and inflammatory effects of intravenous high-dose furosemide plus hypertonic saline solutions (HSS) compared with repeated paracentesis and a standard oral diuretic schedule, in patients with cirrhosis and refractory ascites. Methods 59 consecutive cirrhotic patients with refractory ascites unresponsive to outpatient treatment. Enrolled subjects were randomized to treatment with intravenous infusion of furosemide (125-250mg⁄bid) plus small volumes of HSS …

Liver CirrhosisMaleLeptinCirrhosisPhysiologyPeptide Hormonesmedicine.medical_treatmentdiureticlcsh:MedicineVisfatinPathology and Laboratory MedicineFurosemide; Hypertonic Saline Solution; TNF-alpha; IL-1beta; IL-6; ANP; BNP; Visfatin; Leptin; cirrhosis; refractory ascites; paracentesis; diureticBiochemistryGastroenterology0302 clinical medicineRecurrenceFurosemideImmune PhysiologyMedicine and Health SciencesParacentesisDiureticslcsh:ScienceImmune ResponseSalineHypertonicInnate Immune SystemMultidisciplinarymedicine.diagnostic_testLiver DiseasesPhysicsLeptinrefractory asciteAscitesClassical MechanicsFurosemideHematologyMiddle AgedBody FluidsBloodTreatment OutcomeCirrhosis030220 oncology & carcinogenesisPhysical SciencesHypermetabolismCytokinesAdministration IntravenousFemale030211 gastroenterology & hepatologyAnatomyInflammation MediatorsANPResearch ArticleTNF-alphamedicine.drugparacentesimedicine.medical_specialtyInflammatory DiseasesImmunologyGastroenterology and HepatologyBlood Plasma03 medical and health sciencesSigns and SymptomsDiagnostic MedicineOsmotic PressureInternal medicinePressuremedicineTonicityHumansAgedInflammationSaline Solution HypertonicIL-6business.industrylcsh:RBiology and Life SciencesMolecular DevelopmentIL-1betamedicine.diseaseHormonesHypertonic salineEndocrinologyImmune Systemlcsh:QHypertonic Saline SolutionDiureticbusinessBiomarkersDevelopmental BiologyBNPcirrhosi
researchProduct

Potentially inappropriate use of furosemide in a very elderly population: An observational study

2017

International audience; ObjectiveLittle is known about furosemide prescription modalities in elderly people. We describe furosemide prescription in ambulatory elderly patients.MethodsAll patients aged over 80 years, affiliated to Mutualité Sociale Agricole de Bourgogne, a French regional health insurance plan, with a medical prescription delivered in March 2015, were retrospectively included.ResultsAmong 15 141 patients with a median age of 86 years, comprising 61.3% of women, 3937 patients (26%) had a prescription for furosemide. Severe heart failure was the most common chronic comorbidity (27.7%). Furosemide was considered a long-term therapy for almost all patients (98.7% with prescripti…

Liver CirrhosisMalePediatricsmedicine.medical_specialtyAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsInappropriate Prescribing[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology030204 cardiovascular system & hematologyDrug PrescriptionsNephropathy03 medical and health sciences0302 clinical medicineFurosemidemedicineHumans030212 general & internal medicineMedical prescriptionRenal Insufficiency ChronicDiureticsRetrospective StudiesAged 80 and overHeart Failurebusiness.industryAge FactorsFurosemideRetrospective cohort studyGeneral Medicinemedicine.diseaseComorbidityHeart failureAmbulatoryObservational studyFemalebusinessmedicine.drug
researchProduct

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

2018

Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly…

Liver CirrhosisMaleTime FactorsCirrhosisKaplan-Meier Estimatelaw.inventionascites0302 clinical medicineHepatorenal syndromeRandomized controlled trialFurosemidelawAscitesClinical endpointParacentesisDiureticsalbumin decompensated cirrhosiMineralocorticoid Receptor AntagonistsSettore MED/12 - GastroenterologiaMedicine (all)Hazard ratioGeneral MedicineMiddle AgedSurvival RateCirrhosis030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyQuality-Adjusted Life Yearsmedicine.symptomHyponatremiamedicine.medical_specialty03 medical and health sciencesAlbuminsInternal medicinemedicineHumansSurvival ratealbuminAgedbusiness.industrycirrhosis; albumin; ascitesmedicine.diseaseClinical trialalbumin cirrhosis ascites liver decompensationQuality of LifeHyperkalemiabusinessEsophagus Varices Portal Hypertension Varicosis
researchProduct

Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound

2005

Various particle sizes of spironolactone as a model low solubility drug were formulated to yield micro-and nanosuspensions of the type solid lipid nanoparticles and DissoCubes. Seven oral and one i.v. formulations were tested in an in vivo pharmacokinetic study in rats with the aim of characterizing the bioavailability of spironolactone on the basis of its metabolites canrenone and 7-alpha-thiomethylspirolactone. In addition, a dose escalation study was carried out using nonmicronized spironolactone suspension as well as a nanosuspension type DissoCubes. On the basis of AUC as well as Cmax ratios, three groups of formulations were distinguished. The biggest improvement was seen with a solid…

MaleChemistry PharmaceuticalCmaxAdministration OralBiological AvailabilityPharmaceutical ScienceSpironolactonePharmacologyDrug Delivery SystemsPharmacokineticsPulmonary surfactantOral administrationDrug DiscoverySolid lipid nanoparticlemedicineAnimalsCanrenoneRats WistarSolubilityDiureticsPharmacologyChemistryOrganic ChemistryRatsBioavailabilityArea Under Curvemedicine.drugDrug Development and Industrial Pharmacy
researchProduct

Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure.

2015

Introduction Diuretic responsiveness in patients with chronic heart failure (CHF) is better assessed by urine production per unit diuretic dose than by the absolute urine output or diuretic dose. Diuretic resistance arises over time when the plateau rate of sodium and water excretion is reached prior to optimal fluid elimination and may be overcome when hypertonic saline solution (HSS) is added to high doses of furosemide. Methods Forty-two consecutively hospitalized patients with refractory CHF were randomized in a 1:1:1 ratio to furosemide doses (125 mg, 250 mg, 500 mg) so that all patients received intravenous furosemide diluted in 150 ml of normal saline (0.9%) in the first step (0–24 h…

MaleDose–response curves; Furosemide; Heart failure; Hypertonic saline; Refractory chronic heart failure; Pharmacology (medical); Medicine (all)medicine.medical_treatmentSodiumchemistry.chemical_elementHypertonic salineRefractoryDrug toleranceFurosemidemedicineRefractory chronic heart failureHumansPharmacology (medical)DiureticsAgedOriginal ResearchMedicine(all)Aged 80 and overHeart FailureSaline Solution HypertonicDose-Response Relationship Drugbusiness.industryMedicine (all)Osmolar ConcentrationSodiumFurosemideGeneral MedicineDrug ToleranceMiddle Agedmedicine.diseaseHypertonic salineDose–response relationshipchemistryHeart failureAnesthesiaChronic DiseaseDrug Therapy CombinationFemaleDiureticDose–response curvebusinessDose–response curvesmedicine.drugAdvances in therapy
researchProduct

In vivo and in vitro antioxidant properties of furosemide

2003

The aim of this study was to investigate in vivo and in vitro antioxidant properties of furosemide. In vitro, human red blood cells were submitted to oxidative stress (AAPH), in absence or in presence of different concentrations of furosemide. Potassium efflux was measured in order to quantify the oxidative stress after the action of AAPH on red blood cells. Allophycocyanin assay was also used to investigate antioxidant capacities of furosemide. For the in vivo experiment, male Wistar rats were used. A control group (n = 5) was treated by a daily intraperitoneal injection of saline solution (0.2 ml); 2 other groups (J0 and J+) were treated for 7 days by one daily intraperitoneal injection o…

MaleErythrocytesAntioxidantmedicine.medical_treatmentIntraperitoneal injectionAmidinesOxidative phosphorylationIn Vitro TechniquesPharmacologymedicine.disease_causeAntioxidantsGeneral Biochemistry Genetics and Molecular BiologyFurosemideIn vivomedicineAnimalsHumansGeneral Pharmacology Toxicology and PharmaceuticsDiureticsSalineChemistryPhycocyaninFurosemideFree Radical ScavengersGeneral MedicineIn vitroRatsOxidative StressAnesthesiaPotassiumOxidative stressmedicine.drugLife Sciences
researchProduct

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-l…

2009

Udgivelsesdato: 2009-Jun-20 BACKGROUND: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety. METHODS: In a multicentre, open-label trial, 4447 patients with type 2 diabetes on metformin or sulfonylurea monotherapy with mean haemoglobin A(1c) (HbA(1c)) of 7.9% were randomly assigned to addition of rosiglitazone (n=2220) or to a combination of metformin and sulfonylurea (active con…

MaleMyocardial InfarctionAdministration OralType 2 diabeteslaw.inventionFractures BoneRandomized controlled triallawNeoplasmsClinical endpointMyocardial infarctionrosiglitazone; cardiovascular outcomesProspective StudiesDiureticsGeneral MedicineMiddle AgedMetforminMetforminHospitalizationStrokeDrug Therapy CombinationFemaleRosiglitazonemedicine.drugmedicine.medical_specialtyRosiglitazoneSex FactorsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsAngina UnstableDiabetes Rosiglitazone Cardiovascular RiskHemoglobin A GlycosylatedGlycated HemoglobinHeart FailureIntention-to-treat analysisbusiness.industryBody WeightCholesterol HDLCholesterol LDLtype 2 diabetes; rosiglitazonemedicine.diseaseDrug UtilizationSurgerySulfonylurea CompoundsDiabetes Mellitus Type 2ThiazolidinedionesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessLancet (London, England)
researchProduct

Changes in estimating echocardiography pulmonary capillary wedge pressure after hypersaline plus furosemide versus furosemide alone in decompensated …

2011

BACKGROUND: The aim of the study was to verify the effects of hypertonic saline solution (HSS) plus a high furosemide dose and light restriction of sodium intake compared with a high-dose infusion of furosemide alone on pulmonary capillary wedge pressure (PCWP), as determined by Doppler echocardiography and tissue Doppler imaging in patients suffering from decompensated heart failure. METHODS AND RESULTS: Consecutive patients in New York Heart Association functional class IV, unresponsive to oral high doses of furosemide up to 250-500 mg/d and/or combinations of diuretics, with ejection fraction <40%, serum creatinine <2 mg/dL, blood urea nitrogen ≤60 mg/dL, reduced urinary volume (<500 mL/…

MaleSettore MED/09 - Medicina Internamedicine.medical_treatmentHemodynamicsDoppler echocardiographyDouble-Blind MethodFurosemidemedicinePlethysmographHumansPlethysmography ImpedancePulmonary Wedge PressurePulmonary wedge pressureDiureticsAgedAged 80 and overHeart FailureSaline Solution HypertonicEjection fractionmedicine.diagnostic_testDiuretics Saline Solution Hypertonic Furosemide PCWPbusiness.industryFurosemidemedicine.diseaseEchocardiographyHeart failureAnesthesiaFemaleDiureticCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST tria…

2010

Introduction: Systolic hypertension is very common in the elderly and is strongly associated with the risk of cardiovascular and cerebrovascular events. The control of systolic hypertension is difficult and most patients require combination antihypertensive therapy. Few data are available regarding the efficacy of angiotensin II receptor antagonists on systolic hypertension of the elderly. The aim of this double-blind, double-dummy, randomized, parallel-group, multicenter study was to assess the efficacy of eprosartan 600 mg in combination with hydrochlorothiazide (HCTZ)12.5 mg in comparison with losartan 50 mg in combination with HCTZ 12.5 mg, in reducing blood pressure in elderly patients…

MaleSystolic hypertensionOffice VisitsPharmacologySeverity of Illness Indexlaw.inventionHydrochlorothiazideRandomized controlled triallawAngiotensin II Type 1 Receptor BlockerPharmacology (medical)DiureticsImidazolesGeneral MedicineBlood Pressure Monitoring AmbulatoryAntihypertensive AgentLosartanHydrochlorothiazideTreatment OutcomeAcrylatesHypertensionCardiologyDrug Therapy CombinationFemaleDrug MonitoringHumanmedicine.drugmedicine.medical_specialtyAmbulatory blood pressureSystoleLosartan/hydrochlorothiazideThiopheneselderly patientselderlyLosartanStatistics NonparametricDouble-Blind MethodThiopheneInternal medicinemedicineDiureticHumansImidazoleAntihypertensive AgentsAgedAnalysis of Variancebusiness.industryeprosartanEprosartanmedicine.diseaseambulatory blood pressure monitoringAcrylateBlood pressureOffice VisitbusinessAngiotensin II Type 1 Receptor BlockersAdvances in therapy
researchProduct